Literature DB >> 16448762

Stenotrophomonas maltophilia bacteremia in burn patients.

Wen-Ping Tsai1, Chung-Lin Chen, Wen-Chien Ko, Shin-Chen Pan.   

Abstract

Stenotrophomonas maltophilia has been increasingly reported as a nosocomial opportunistic pathogen in debilitated patients, including burn patients. There is, however, only one published report in English that discusses S. maltophilia bacteremia in burns. We performed a retrospective chart review and statistical analysis of the incidence, the duration of hospital stays before a diagnosis of bacteremia, antimicrobial susceptibility, prognosis, and mortality risk factors in burn patients. From January 1996 to December 2004, 14 episodes of S. maltophilia bacteremia in 13 of 666 patients admitted to the burn center at our hospital were identified. The patients, nine males and four females, ranged in age from 1 to 76 years (mean: 42.9+/-24.4 years). Eleven injuries were from flame burns and two were from scald burns. The mean total burned surface area (TBSA) was 47+/-30.2% and mean prognostic burn index (PBI) was 81.7+/-31.3. The average annual incidence was 2.3 episodes per 1000 admissions, and no outbreak cluster was noticed. The mean hospital stay before bacteremia was 19.8+/-11.9 days. Most isolates were susceptible to ticarcillin-clavulanate (87.5%) and moxalactam (85.7%). The overall mortality was 30.7% (4/13) and correlated significantly with TBSA (P<0.01) and PBI (P<0.05). The incidence of S. maltophilia bacteremia was higher in hospitalized burn patients than in hospitalized non-burn patients. Different antimicrobial susceptibility patterns may exist, especially in different geographic regions. Awareness of the possibility of infection by this opportunistic pathogen and commencement of adequate antibiotics treatment, especially after 3 weeks of intensive care, should be incorporated into the strategy of treatment in major burn patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16448762     DOI: 10.1016/j.burns.2005.08.016

Source DB:  PubMed          Journal:  Burns        ISSN: 0305-4179            Impact factor:   2.744


  9 in total

1.  Immunostimulatory properties of the emerging pathogen Stenotrophomonas maltophilia.

Authors:  Valerie J Waters; Marisa I Gómez; Grace Soong; Sunil Amin; Robert K Ernst; Alice Prince
Journal:  Infect Immun       Date:  2007-01-12       Impact factor: 3.441

Review 2.  Antibiotic treatment for Stenotrophomonas maltophilia in people with cystic fibrosis.

Authors:  Reshma Amin; Valerie Waters
Journal:  Cochrane Database Syst Rev       Date:  2016-07-14

3.  Stenotrophomonas maltophilia infection among young children in a cardiac intensive care unit: a single institution experience.

Authors:  Ciji Arthur; Xinyu Tang; Jose R Romero; Jeffrey G Gossett; Nada Harik; Parthak Prodhan
Journal:  Pediatr Cardiol       Date:  2014-10-08       Impact factor: 1.655

4.  Patterns of multidrug resistant organism acquisition in an adult specialist burns service: a retrospective review.

Authors:  Heather Cleland; Lincoln M Tracy; Alex Padiglione; Andrew J Stewardson
Journal:  Antimicrob Resist Infect Control       Date:  2022-06-13       Impact factor: 6.454

5.  Intensive care unit-acquired Stenotrophomonas maltophilia: incidence, risk factors, and outcome.

Authors:  Saad Nseir; Christophe Di Pompeo; Hélène Brisson; Florent Dewavrin; Stéphanie Tissier; Maimouna Diarra; Marie Boulo; Alain Durocher
Journal:  Crit Care       Date:  2006       Impact factor: 9.097

Review 6.  Stenotrophomonas maltophilia as an Emerging Ubiquitous Pathogen: Looking Beyond Contemporary Antibiotic Therapy.

Authors:  Anthony A Adegoke; Thor A Stenström; Anthony I Okoh
Journal:  Front Microbiol       Date:  2017-11-30       Impact factor: 5.640

7.  Draft Genome Sequences of Nine Stenotrophomonas maltophilia Isolates from a Freshwater Catchment Area in Hong Kong.

Authors:  A C Y Cheung; G K K Lai; S D J Griffin; F C C Leung
Journal:  Microbiol Resour Announc       Date:  2022-06-23

8.  Antibiotic treatment for Stenotrophomonas maltophilia in people with cystic fibrosis.

Authors:  Reshma Amin; Nikki Jahnke; Valerie Waters
Journal:  Cochrane Database Syst Rev       Date:  2020-03-18

9.  Antimicrobial susceptibility of hospital acquired Stenotrophomonas maltophilia isolate biofilms.

Authors:  Erlin Sun; Gehong Liang; Lining Wang; Wenjie Wei; Mingde Lei; Shiduo Song; Ruifa Han; Yubao Wang; Wei Qi
Journal:  Braz J Infect Dis       Date:  2016-05-13       Impact factor: 3.257

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.